Stable lentiviral vector producer cell line for a scalable manufacture

Published: 2 December 2021
Roy Liu

Watch the video or read the poster to learn about:

  • The benefits of using stable cell lines to produce lentivirus
  • The advantages the EuLV lentiviral production system offers as compared to plasmid transfection
  • An example 25L-scale LVV production process in WAVE Bioreactor

Mr Liu graduated from the Hong Kong University of Science and Technology with a Master degree in Biotechnology. He previously worked in Bio-techne and InvivoGen. Mr Liu joined Eureka Bio in 2016 as COO, and he has extensive knowledge in Gene and Cell therapy industry, and is experienced in business development, project management, process development, cGMP etc.

Read now